All updates
All updates
today 47临床试验登记评分3333 临床试验登记评分3333 A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
临床试验登记评分3333 A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis
临床试验登记评分2222 US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
临床试验登记评分2626 RYZ711 Diagnostic Platform Study
临床试验登记评分3232 Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
临床试验登记评分2121 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
临床试验登记评分3030 DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
临床试验登记评分3535 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
临床试验登记评分3333 Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
临床试验登记评分2828 Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
中文产业新闻Chinese source评分7070 ArriVent伏美替尼FURVENT三期一线治疗EGFR exon20ins NSCLC未达主要终点
中文产业新闻Chinese source评分6363 艾力斯伏美替尼海外FURVENT三期未达主要终点，合作方ArriVent美股单日暴跌近50%
中文产业新闻Chinese source评分5353 华中科技大学团队在Nature Medicine报告体内BCMA CAR-T治疗骨髓瘤4例均缓解
BioSpace精选评分7171 Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
中文产业新闻精选Chinese source评分6767 SMARTEST 研究：达格列净在早期 2 型糖尿病中未优于二甲双胍
BioSpace评分6262 ArriVent sheds nearly half of value on late-stage lung cancer miss
中文产业新闻精选Chinese source评分8181 礼来瑞他鲁肽III期结果同日登NEJM与柳叶刀，近四分之一肥胖者体重下降超35%
STAT News评分3838 ER visits from people born outside the U.S. dropped after ICE raids
BioPharma Dive评分6666 A Takeda spinout builds case for its Parkinson’s drug
中文产业新闻精选Chinese source评分8484 武田泽索昔替尼头对头氘可来昔替尼 III 期试验达到主要终点
临床试验登记评分3535 A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
监管与产业动态评分1717 Kairos seizes moment to push prostate cancer prospect into earlier setting - Fierce Biotech
监管与产业动态评分3333 AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy - Fierce Pharma
监管与产业动态评分3333 ArriVent’s phase 3 lung cancer trial flops, sinking stock - Fierce Biotech
监管与产业动态精选评分6060 Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy
中文产业新闻精选Chinese source评分7171 伏美替尼FURVENT三期试验未达PFS主要终点 公司股价暴跌60%
中文产业新闻Chinese source评分6868 伏美替尼FURVENT全球三期试验一线治疗EGFR exon20ins非小细胞肺癌未达主要终点
中文产业新闻Chinese source评分6363 艾力斯伏美替尼一线EGFR exon20ins NSCLC三期未达PFS主要终点
中文产业新闻Chinese source评分4040 余额不足，Caribou停止异体CAR-T临床3期，盘后大跌
监管与产业动态精选评分3838 Signal or noise? > Gene therapy tied to slower functional decline in Huntington’s at 4 years - Huntington's Disease News >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharmaceutical #pharma
顶刊论文（社媒热度）精选评分6363 Iron or Multiple Micronutrient Powder Supplements With Malaria Chemoprevention in Rural Malawian Children: The IRMA Randomized Clinical Trial.
文献与产业新闻评分2424 Simultaneous immune checkpoint blockade-associated diabetes mellitus and thyrotoxicosis
中文产业新闻Chinese source评分3434 诺和诺德启动zenagamtide国际多中心Ⅲ期临床试验，针对ASCVD合并超重或肥胖人群
中文产业新闻精选Chinese source评分8585 恒瑞医药口服小分子GLP-1激动剂HRS-7535三期对达克格列净显示非劣效与优效
中文产业新闻Chinese source评分6767 Vaxcyte 31价肺炎球菌结合疫苗 VAX-31 三期 OPUS-1 公布顶线数据
中文产业新闻Chinese source评分6565 伏美替尼全球Ⅲ期FURVENT失利：一线治疗EGFR 20ins未胜化疗
中文产业新闻精选Chinese source评分7171 艾力斯伏美替尼全球3期FURVENT研究未达PFS主要终点
中文产业新闻Chinese source评分6565 英国随机对照试验：DC 疫苗联合 TACE 将中晚期肝癌无进展生存期延长至 18.6 个月
中文产业新闻Chinese source评分6060 ArriVent伏美替尼FURVENT全球三期临床失败，股价单日大跌52%